Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

611 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group.
Icli F, Akbulut H, Uner A, Yalcin B, Baltali E, Altinbas M, Coşkun S, Komurcu S, Erkisi M, Demirkazik A, Senler FC, Sencan O, Büyükcelik A, Boruban C, Onur H, Zengin N, Sak SD. Icli F, et al. Among authors: yalcin b. Br J Cancer. 2005 Feb 28;92(4):639-44. doi: 10.1038/sj.bjc.6602388. Br J Cancer. 2005. PMID: 15726120 Free PMC article. Clinical Trial.
ABO and Rh blood groups and risk of colorectal adenocarcinoma.
Urun Y, Ozdemir NY, Utkan G, Akbulut H, Savas B, Oksuzoglu B, Oztuna DG, Dogan I, Yalcin B, Senler FC, Onur H, Demirkazik A, Zengin N, Icli F. Urun Y, et al. Among authors: yalcin b. Asian Pac J Cancer Prev. 2012;13(12):6097-100. doi: 10.7314/apjcp.2012.13.12.6097. Asian Pac J Cancer Prev. 2012. PMID: 23464411 Free article.
Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study.
Ozdemir N, Abali H, Vural M, Yalcin S, Oksuzoglu B, Civelek B, Oguz D, Bostanci B, Yalcin B, Zengin N. Ozdemir N, et al. Among authors: yalcin b, yalcin s. Cancer Chemother Pharmacol. 2014 Dec;74(6):1139-47. doi: 10.1007/s00280-014-2586-6. Epub 2014 Sep 19. Cancer Chemother Pharmacol. 2014. PMID: 25234436 Clinical Trial.
Resistance to androgen-pathway drugs in prostate cancer.
Şendur MA, Akıncı MB, Yalçın B. Şendur MA, et al. Among authors: yalcin b. N Engl J Med. 2014 Dec 4;371(23):2233. doi: 10.1056/NEJMc1412594. N Engl J Med. 2014. PMID: 25470701 No abstract available.
611 results